Download Files:
TGFβRI-IN-3
SKU
HY-132290-10 mg
Category Reference compound
Tags Cancer; Inflammation/Immunology, TGF-beta/Smad, TGF-β Receptor
$240 – $1,650
Products Details
Product Description
– TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology[1].
Web ID
– HY-132290
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C28H23N3O2S
References
– [1]Kharbanda A, et al. Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology [published online ahead of print, 2021 Aug 12]. Eur J Med Chem. 2021;225:113763.
CAS Number
– 2763602-67-9
Molecular Weight
– 465.57
Compound Purity
– 98.04
SMILES
– CS(C1=CC=C(C=C1)C2=CC=C3C(NC4=CC=NC(C5=CC(C)=CC=C5)=C4)=CC=NC3=C2)(=O)=O
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– TGF-β Receptor
Pathway
– TGF-beta/Smad
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.